Filing Details

Accession Number:
0001209191-20-024928
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-04-17 18:03:40
Reporting Period:
2020-04-15
Accepted Time:
2020-04-17 18:03:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
906709 Nektar Therapeutics NKTR Pharmaceutical Preparations (2834) 943134940
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1227886 Robert Chess C/O Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco CA 94158
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-04-15 8,000 $9.24 284,973 No 4 M Direct
Common Stock Disposition 2020-04-15 7,803 $18.36 277,170 No 4 S Direct
Common Stock Disposition 2020-04-15 197 $19.02 276,973 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2020-04-15 8,000 $0.00 8,000 $9.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
16,000 2013-09-30 2020-09-13 No 4 M Direct
Footnotes
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. This transaction was executed in multiple trades at prices ranging from $17.96 to $18.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
  3. This transaction was executed in multiple trades at prices ranging from $19.01 to $19.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.